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Heart failure (HF) remains a large medical problem, and prevention of decompensation and HFrelated hospitalizations is important, not only for the patient, but also from an economic point of view. Close monitoring is crucial, and can be done through a whole spectrum of modalities. This ranges from a (nurse-based) disease management program, to structured telephone support, to remote or telemonitoring with or without the use of an implantable device [1] [2] [3] .
Disease management programs, usually with a specialized nurse, and in the hospital are implemented on a large scale, but the optimal level and intensity of care is still unclear 4 .
Structured telephone support may be useful, and a recent meta-analysis showed a reduction in HF hospitalization, but no effect on mortality 2 . Remote, home or tele-monitoring using a number of (relatively simple) non-invasive variables such as heart rate, blood pressure, and body weight was also examined in a number of studies, and the same meta-analysis showed that this method reduced both hospitalizations and mortality 2 . However, 2 recent large studies not included in that analysis did not show such a positive effect 5, 6 . In the American TELE-HF (Telemonitoring to improve outcomes in HF) Study 5 and in the German TIM-HF (Telemedical Intervention
Monitoring in HF) study 6 , which together randomized 2362 HF patients, no effect on HF hospitalizations or mortality was observed.
In recent years, a number of studies in the field of telemonitoring have been published that measured invasive variables. In the COMPASS-HF (Chronicle Offers Management To
Patients with Advanced Signs and Symptoms of HF) study 7 a strategy based on measurement of right-sided intracardiac pressures (with a special transvenous lead: Chronicle, Medtronic) was examined. The primary (composite) endpoint showed a non-significant 21% reduction, but there was a statistically significant, 36% reduction in the time to first hospitalization in the 301 patients studied 7 . More recently, the results from CHAMPION (CardioMEMS Heart sensor of (relatively simple) non-invasive variables such as heart rate, blood pressure, an an nd d bo body dy dy w w wei ei eigh ght was also examined in a number of studies, and the same meta-analysis showed that this method e edu du uce ce ed d d bo bo both th th hos os spi pi pita t lizations and mortality 2 . Ho o owe we wev ver, 2 recent la la arg r e e st st stu ud udies not included in that an nal al lys y is did n not ot s sh h how w su u uch ch ch a a a p p pos osit it tiv iv ive e e ef eff f fect 5 5,6 5 . . In t th he A A Am me meri rica an n TE TE TELE LE-H -H -F F (T (T (Te el elem em mon on onit ito o orin in ng g t to t
Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III HF patients) have become available 8 . In 550 patients, the value of daily measurement of pulmonary artery pressure measurements was examined. The device used has a passive, wireless, radiofrequency sensor without batteries or leads and results from the device were only available to the physician (through transmission) who could then change (increase) drug treatment. After 6 months, there was a significant 28% reduction in HF related hospitalizations in the treatment group.
Measurement of left-sided (atrial) pressures has only been examined in a small study 9 , which showed potentially interesting findings, but this method may be more complicated, and largescale data are awaited.
Some diagnostic variables can also be collected when built into an Implantable
Cardioverter Defibrillator (ICD) or a Cardiac Resynchronization therapy (CRT) device 1, 3 . The use of ICD and CRT has markedly increased in recent years 10 , and both have received a recommendation in HF patients with a decreased ejection fraction in current guidelines 11 . The diagnostic variables which can be recorded using ICD/CRT devices include measurement of intrathoracic impedance to track changes in thoracic fluid content, heart rate variability, patients' physical activity level and (atrial and ventricular) arrhythmias 1 .
In the PARTNERS (Program to
Access and Review Trending Information and Evaluate Correlation to symptoms in patients with HF) study 12 , an increased fluid index (or drop in intrathoracic impedance) was the most sensitive parameter to detect HF hospitalizations. A number of smaller studies measuring intrathoracic impendance (using Optivol, Medtronic) had also shown promising results, but two recent, larger studies failed to confirm these favorable findings 13, 14 . In the SENSE-HF (Sensitivity of InSync Sentry Optivol feature for the prediction of HF) study 13 in 501 patients, the sensitivity of intrathoracic fluid monitoring changed over time, and was lower than earlier reported (up to Some diagnostic variables can also be collected when built into an Impla an nt ntab ab able e e Cardioverter Defibrillator (ICD) or a Cardiac Resynchronization therapy (CRT) device 1, 3 . The us se e of of of I I ICD CD CD a a n n nd C C CR RT RT has markedly increased in r r rec ec e e ent years 10 , an nd d d bo oth th th h h have received a e eco o omm m endati ion on n in n n H HF HF p p pat at atie ie ient nt nts s wi wi with th h a a a d d decre e eas sed ej je ecti ti io on on f f fra ract ctio io on n in n c cu ur urre rent nt nt g g gui uide de deli li ine ne n s s s 11 1 1 . . Th Th The e e di diag ag agno no nost stic ic v v va ar aria iab b ble es es w w whi hi ich ch c can an a b b be e e re re reco co ord rd ded ed ed u us s sin in ing g g IC C CD D/ D/CR CR CRT T T de de devi vi ice e es s s in in ncl clu ud ude e e me me meas as sur ur urem em men n nt t of of f ntrathoracic c im im impe pe peda da danc nc ce e e to o o t t tra ra rack k k c c cha ha ang ng ges es e i i in n n th th hor or o ac ac acic ic ic f f lu u uid id id c c con on onte te tent nt n , he he hear ar art t t ra ra rate te te v v var ar aria ia iabi bi b li li lity t , patients' 42% after 6 months), while the positive predictive value (and specificity) were also low 13 . The DOT-HF (Diagnostic Outcome Trial in HF) 14 was designed to examine whether ambulatory monitoring of intrathoracic fluid monitoring (with Optivol, Medtronic) could improve outcome in patients with HF. However, because of slow enrolment and changes in monitoring technology, the trial was stopped after only 345 of the planned 2400 patients were enrolled. Analysis of these 345 patients showed, that there was an increase of borderline statistical significance of the primary endpoint of all-cause mortality and HF hospitalizations in the (Optivol) access arm that was mainly due to the latter 14 . The number of outpatient visits ("health care utilizations") was also markedly (almost 3-fold) higher in the access arm.
In the present issue of Circulation, Landolina et al. 15 b be een n en implanted ed d. Th Th he e p p prim im mar ar ary y y e en endp dp po oi oint nt t w w was t t the e e rat t te e of em em mer er rge e enc ncy y he heal al lth t t c ca care e e u u uti tili liz za zati ti tion on ns, , , d d def ef efin n ned as s v v vis is sit it its s to to t t the he h e eme me merg rge e enc cy cy dep ep par ar rtm tm tmen e ent t an an and d d u ur urge ge gent nt n (u un unpl pl plan an anne ne ned) d) ) i i n n-n-of of ffi fi fice ce e v v vi isi sits ts ts, , fo fo f r r he he hear art t t fa fa ail ilu ur ure, e, , arrhythmias or or or I I ICD CD D-r -rel el e at a a ed d d e e eve ve v nt nt n s. s. s H H Hal l lf f f of of of t t the he he p p pa a ati ti ien en nts t w w wer er ere e e ra ra and nd ndom m miz iz ized ed ed t t to o o th th he e e re re remo mo mote te arm, in remote monitoring reduced emergency department/urgent in-office visits and remarked that it increased efficiency for health care providers.
Although these data from the EVOLVO study 15 are important and provide new information, some comments must be made. First, the benefit of the approach as described by the authors, was an "increased efficiency for health care providers and improved quality of care for HF patients". Increased efficiency may be convenient for doctors and nurses, and leads to less anxiety for patients, and possibly lower costs. Less stress may have been present in EVOLVO, and indeed some but not all parameters of quality of life were favourably affected, but the relevance of this finding can be argued, if patients are aware of which of the study arms they participate in. Whether this approach leads to lower costs, we do not know, since they were not reported 15 . Clearly, fewer urgent visits will reduce costs, but setting up and maintaining a system such as CareLink to analyze and act on transmitted data also carries a price tag, and it would be interesting to see a health-economics analysis of this EVOLVO study. Second, "improved quality of care" would hopefully improve outcome, i.e. reduce (heart failure) hospitalizations and ultimately, mortality, but those effects were not observed in the EVOLVO study. Clearly, the study was not powered for this, but trends were also not observed. Third, in patients in the remote arm, all audible alerts were off (apart from system-integrity alerts), since all alerts regarding clinical management were transmitted through the CareLink Network. In contrast, in patients in the control arm, the alerts were turned on for audible notification (only). Although the EVOLVO study was designed before the results of DOT-HF 14 became available, it is somewhat remarkable that patients in the control arm received audible alerts, since it had not been proven at the time that such audible alerts would be beneficial. Indeed, given the negative findings of DOT-HF 14 , this may have caused bias against the control arm. The authors report that 79 (of the participate in. Whether this approach leads to lower costs, we do not know, since e the he h y y y we we were re re n n no ot eported 15 . Clearly, fewer urgent visits will reduce costs, but setting up and maintaining a system u uch ch h a a as s s Ca Ca Care re r L L Link nk k t t to o analyze and act on transmitt tt ted ed e data also carri ri ies e e a a p p pri ri rice c tag, and it would be n nte e ere r sting to s see ee e a a a h hea ealt t th-h h-ec ec econ on onom om mic ic cs s a an ana alys sis of t th thi is E E EV VO VOLV LV LVO O st tud udy. y S ec eco on ond d, d, " "im im imp pr pro ov ved ed ed qu qual al a it it ity y y of of c c car ar are" e" w w wo ou ould ld d h h hop opef f ful ul u ly ly ly im im impr prov ov ove e e ou ou outc c com om ome, , i.e e e. re re red du duce ce ce ( (h he hea a art rt r f f fa ail lu lure re e) ) ) ho ho h sp sp spit it ital aliz iz zat at tio ion n ns a a and ultimately, mo mo ort rt tal al lit it ity, y, y b b but u u t tho ho hose s s e e eff ff ffec ec cts t w w wer er ere e e no no not t t ob ob obse se erv rved ed ed i i in n n th th the e e EV EV EVOL OL OLVO VO VO s s stu tu udy dy dy. . Cl Cl C ea ea e rly, the 256=31%) alerts were audible, and that many were apparently not recognized by the patients, or the clinician did not consider them relevant. Fourth and last, in the present study Optivol alerts (intrathoracic impedance changes) were again the most common alert condition (in 274/315
cases [87%] in the remote arm, and in 231/256 cases [90%] in the control arm), which agrees with earlier reports 13, 14 . In the remote arm, after the data were analyzed in more detail using the CareLink information, many patients could however, be reassured and alerts were (most likely) false positives. This brings into attention again sensitivity, but more importantly, specificity issues regarding the use of intrathoracic impedance monitoring 13, 14 .
What can be concluded from the EVOLVO study 15 and what do these data add to the current thinking regarding home or telemonitoring in HF? Although there is a lively and ongoing debate with regard to the value of home monitoring in HF patients 4, 16 , most people would probably agree that many of the measured variables may have some value in detecting early changes leading to a cardiac decompensation, and that these variables could potentially have a place in the management of HF patients. However, not all abnormal values lead to clinical problems and these variables often fluctuate, and particularly the specificity of abnormalities may be low 14 . Indeed, knowing "too much" may be a problem 17 , and including the patient in the information loop may not always be wise. In case of audible alerts, this may be hard to ignore, particularly for the patient, who may require treatment or even an urgent hospital visit or overnight stay. The search for an optimal HF disease management program, which will include a home monitoring component in many patients, will continue in the future, and may become a search for the Holy Grail. The EVOLVO study 16 adds an important piece to this puzzle and
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